The vaccine had a 100% success rate during a clinical trial in Guinea.
Subscribe to Vocativ:
Find us everywhere else:
Vocativ explores the nexus of media and technology, where science meets storytelling. We use proprietary technology to examine the uncharted space of the Deep Web, covering topics that are vital to our changing world. us for more!